02 September 2019
Visiongain has launched a new pharma report Top Pre-Filled Injection Device Manufacturers 2019-2029: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services.
Pre-filled syringes provide users with a number of advantages over other drug delivery systems. These include simplified storage and disposal, shorter preparation and administration time and reduced risk of medication errors. For drug manufacturers, there are also numerous advantages to pre-filled syringes. Filling syringes rather than vials cuts overfill rates, reducing wastage, and also eliminates material costs as there is no need for vials as well as syringes.
The lead analyst of the report commented "Most companies have invested in new manufacturing facilities or sales offices in emerging markets, to take advantage of lower cost manufacturing, as well as in order to appeal to emerging market drug developers. A particular target group among these companies are biosimilar developers looking to bring their drugs to developed markets. Companies have also invested in products suitable for administration of these biosimilars, as well as novel biologics. These include dual-chamber syringes and cartridges, lyophilisation and reconstitution tools, sensitive syringe coatings and polymer syringes."
Leading companies featured in the report include Aptar Stelmi, Becton, Dickinson, & Co (BD), Bespak Injectables, Boehringer Ingelheim, Catalent, Dätwyler Holding, Gerresheimer, Haselmeier, Laboratorios Farmacéuticos ROVI and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.